These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 30029908)
1. Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin. Corrêa Barros LP; Del Rio KP; Carvalho TDSC; Pinto MDCFR; de Moura KCG; Halicki PCB; Ramos DF; da Silva PEA Tuberculosis (Edinb); 2018 Jul; 111():198-201. PubMed ID: 30029908 [TBL] [Abstract][Full Text] [Related]
2. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis. Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913 [TBL] [Abstract][Full Text] [Related]
3. 1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis. Moura KC; Carneiro PF; Pinto Mdo C; da Silva JA; Malta VR; de Simone CA; Dias GG; Jardim GA; Cantos J; Coelho TS; da Silva PE; da Silva EN Bioorg Med Chem; 2012 Nov; 20(21):6482-8. PubMed ID: 23000294 [TBL] [Abstract][Full Text] [Related]
4. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562 [TBL] [Abstract][Full Text] [Related]
5. Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles. Kumarasingam K; Vincent M; Mane SR; Shunmugam R; Sivakumar S; Uma Devi KR Int J Mycobacteriol; 2018; 7(1):84-88. PubMed ID: 29516891 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids. Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427 [TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens. Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383 [TBL] [Abstract][Full Text] [Related]
8. Rapid phenotypic assay of antimycobacterial susceptibility pattern by direct mycobacteria growth indicator tube and phage amplified biological assay compared to BACTEC 460 TB. El-Sayed Zaki M; Goda T Tuberculosis (Edinb); 2007 Mar; 87(2):102-8. PubMed ID: 17035089 [TBL] [Abstract][Full Text] [Related]
9. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model. de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996 [TBL] [Abstract][Full Text] [Related]
10. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Vilchèze C; Kim J; Jacobs WR Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757 [TBL] [Abstract][Full Text] [Related]
11. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action. Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902 [TBL] [Abstract][Full Text] [Related]
12. In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis. Ge F; Zeng F; Liu S; Guo N; Ye H; Song Y; Fan J; Wu X; Wang X; Deng X; Jin Q; Yu L J Med Microbiol; 2010 May; 59(Pt 5):567-572. PubMed ID: 20075118 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. Imperiale BR; Di Giulio ÁB; Adrián Cataldi A; Morcillo NS J Antibiot (Tokyo); 2014 Nov; 67(11):749-54. PubMed ID: 24894185 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of isoimperatorin, alone and in combination, against Mycobacterium tuberculosis. Guo N; Wu J; Fan J; Yuan P; Shi Q; Jin K; Cheng W; Zhao X; Zhang Y; Li W; Tang X; Yu L Lett Appl Microbiol; 2014 Apr; 58(4):344-9. PubMed ID: 24330002 [TBL] [Abstract][Full Text] [Related]
15. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646 [TBL] [Abstract][Full Text] [Related]
19. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China. Jiao WW; Mokrousov I; Sun GZ; Li M; Liu JW; Narvskaya O; Shen AD Chin Med J (Engl); 2007 May; 120(9):814-9. PubMed ID: 17531124 [TBL] [Abstract][Full Text] [Related]
20. In vitro antimycobacterial activity of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione: a new chemical entity against Mycobacterium tuberculosis. Rather MA; Bhat ZS; Lone AM; Maqbool M; Amin S; Bhat BA; Ahmad Z Int J Antimicrob Agents; 2018 Aug; 52(2):265-268. PubMed ID: 29510188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]